Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Arrowhead Research (ARWR) Doses First Patient in ARC-AAT Phase 1 Part B
July 2, 2015 7:34 AM EDTArrowhead Research (Nasdaq: ARWR) announced that it dosed the first patient in Part B of a Phase 1 clinical trial of ARC-AAT. ARC-AAT is Arrowheads RNAi-based drug candidate for the treatment of liver disease associated with the rare genetic disorder alpha-1 antitrypsin deficiency (AATD) that was recently granted orphan drug designation by the United States Food and Drug Administration. The clinical trial is currently enrolling patients at a single center in Australia and the company intends to open additional sites for... More
